1. 首頁 > 生活雜燴 > 健康養生 > >

西利|CCR：早發現這個標志物，就知道為啥有些ER+乳腺癌用不對藥了！( 二 )


因此 ， 總的來說 ， 這些結果都表明 ， 高CCNE1水平可能是內分泌治療+CDK4/6抑制劑反應差的預測標志物 。 這有助于在之后的臨床試驗和臨床治療中幫助篩選更有可能從治療中獲益的患者群體 。
參考文獻：
[1] Howlader N, Altekruse S F, Li C I, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status[J]. JNCI: Journal of the National Cancer Institute, 2014, 106(5).
[2] Dowsett M, Kilburn L, Rimawi M F, et al. Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2-breast cancer[J]. Clinical Cancer Research, 2021.
[3] Johnston S, Puhalla S, Wheatley D, et al. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial[J]. 2019.
[6] Turner N C, Liu Y, Zhu Z, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor–positive metastatic breast cancer[J]. Journal of Clinical Oncology, 2019, 37(14): 1169-1178.
【西利|CCR：早發現這個標志物，就知道為啥有些ER+乳腺癌用不對藥了！】[7] Prat A, Chaudhury A, Solovieff N, et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies[J]. Journal of Clinical Oncology, 2021, 39(13): 1458-1467.